Evaluation of the antihyperalgesic effect of tapentadol in two human evoked pain models – the TapCapMentho pilot trial

References

• Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–1635.
   PubMed Web of Science ®Google Scholar
• Maier C, Baron R, Tolle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150:439–450.
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155:2263–2273.
   PubMed Web of Science ®Google Scholar
• Klein T, Magerl W, Rolke R, et al. Human surrogate models of neuropathic pain. Pain. 2005;115:227–233.
   PubMed Web of Science ®Google Scholar
• Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg. 2008;107:2048–2055.
   PubMed Web of Science ®Google Scholar
• Stegmann JU, Weber H, Steup A, et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin. 2008;24:3185–3196.
   PubMed Web of Science ®Google Scholar
• Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009;25:1551–1561.
   PubMed Web of Science ®Google Scholar
• Biondi D, Xiang J, Benson C, et al. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Pain Physician. 2013;16:E237–46.
   PubMed Web of Science ®Google Scholar
• Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014;17:329–343.
   PubMed Web of Science ®Google Scholar
• Baron R, Martin-Mola E, Muller M, et al. Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. Pain Pract. 2015;15:455–470.
   PubMed Web of Science ®Google Scholar
• Steigerwald I, Schenk M, Lahne U, et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig. 2013;33:607–619.
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30:489–505.
   PubMed Web of Science ®Google Scholar
• Niesters M, Proto PL, Aarts L, et al. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth. 2014;113:148–156.
   PubMed Web of Science ®Google Scholar
• Binder A, Stengel M, Klebe O, et al. Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model. J Pain. 2011;12:764–773.
   PubMed Web of Science ®Google Scholar
• Mahn F, Hullemann P, Wasner G, et al. Topical high-concentration menthol: reproducibility of a human surrogate pain model. Eur J Pain. 2014;18:1248–1258.
   PubMed Web of Science ®Google Scholar
• Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:S2–S15.
   PubMed Web of Science ®Google Scholar
• Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–819.
   PubMed Web of Science ®Google Scholar
• Bee LA, Bannister K, Rahman W, et al. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain. 2011;152:131–139.
   PubMed Web of Science ®Google Scholar
• Meske DS, Xie JY, Oyarzo J, et al. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Neurosci Lett. 2014;562:91–96.
   PubMed Web of Science ®Google Scholar
• Lee YK, Ko JS, Rhim HY, et al. Acute postoperative pain relief with immediate-release tapentadol: randomized, double-blind, placebo-controlled study conducted in South Korea. Curr Med Res Opin. 2014;30:2561–2570.
   PubMed Web of Science ®Google Scholar
• Wasner G, Schattschneider J, Binder A, et al. Topical menthol–a human model for cold pain by activation and sensitization of C nociceptors. Brain. 2004;127:1159–1171.
   PubMed Web of Science ®Google Scholar
• Altis K, Schmidtko A, Angioni C, et al. Analgesic efficacy of tramadol, pregabalin and ibuprofen in menthol-evoked cold hyperalgesia. Pain. 2009;147:116–121.
   PubMed Web of Science ®Google Scholar
• Greenspan JD, McGillis SLB. Stimulus features relevant to the perception of sharpness and mechanically evoked cutaneous pain. Somatosens Mot Res. 1991;8:137–147.
   PubMed Web of Science ®Google Scholar
• Slugg RM, Meyer RA, Campbell JN. Response of cutaneous A- and C-fiber nociceptors in the monkey to controlled-force stimuli. J Neurophysiol. 2000;83:2179–2191.
   PubMed Web of Science ®Google Scholar
• Magerl W, Krumova EK, Baron R, et al. Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain. 2010;151:598–605.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151–162.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37:2302–2309.
   PubMed Web of Science ®Google Scholar
• Taneja A, Di Iorio VL, Danhof M, et al. Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov Today. 2012;17:837–849.
   PubMed Web of Science ®Google Scholar
• von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73:638–652.
   PubMed Web of Science ®Google Scholar
• Oertel BG, Lotsch J. Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research. Br J Pharmacol. 2013;168:534–553.
   PubMed Web of Science ®Google Scholar
• Iacovides S, Avidon I, Baker FC. Does pain vary across the menstrual cycle? A review. Eur J Pain (London, England). 2015;19:1389–1405.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Oertel BG, Ultsch A. Human models of pain for the prediction of clinical analgesia. Pain. 2014;155:2014–2021.
   PubMed Web of Science ®Google Scholar
• Petersen KL, Rowbotham MC. A new human experimental pain model: the heat/capsaicin sensitization model. Neuroreport. 1999;10:1511–1516.
   PubMed Web of Science ®Google Scholar
• Park KM, Max MB, Robinovitz E, et al. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain. 1995;63:163–172.
   PubMed Web of Science ®Google Scholar
• Petersen KL, Jones B, Segredo V, et al. Effect of remifentanil on pain and secondary hyperalgesia associated with the heat–capsaicin sensitization model in healthy volunteers. Anesthesiology. 2001;94:15–20.
   PubMed Web of Science ®Google Scholar
• Hoeben E, Smit JW, Upmalis D, et al. Dose-response relationship after administration of single oral doses of tapentadol in a human pain model using Laser Somatosensory Evoked Potentials (LSEPs) on UVB-irradiated and capsaicin-irritated skin in healthy male subject. Abstract and Poster Keystone Symposium ‘The Neurobiology of Pain and Analgesia’; 2009; Santa Fé.
   Google Scholar